Get started
Author

Carmel Murone

Observed names: C Murone, C. MURONE, C. Murone, Murone, C
Observed institutions: The University of Sydney, National Institutes of Health, The Royal Melbourne Hospital, Memorial Sloan Kettering Cancer Center, The University of Melbourne, Ludwig Cancer Research, La Trobe University, Florey Institute of Neuroscience and Mental Health, Royal Brisbane and Women's Hospital, Austin Hospital, Queen Elizabeth Hospital, Ludwig Cancer Research, Victorian Cancer Biobank, Ludwig Cancer Research, Ludwig Cancer Research, Ludwig Cancer Research, National Cancer Institute, Ludwig Cancer Research, Heidelberg Repatriation Hospital, Olivia Newton-John Cancer Wellness & Research Centre, Austin Health, Wyeth, Olivia Newton-John Cancer Research Institute, The University of Adelaide
ORCID: 0009-0004-9178-9867
Observed ORCID: 0009-0004-9178-9867
OpenAlex ID: A5085902226
A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors
2007 · Andrew M. Scott, Fook-Thean Lee, et al. · Proceedings of the National Academy of Sciences · 223
Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer
2011 · Timothy J. Price, Jennifer E. Hardingham, et al. · Journal of Clinical Oncology · 217
PDF
Correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in gliomas using 18F-fluoromisonidazole, 18F-FDG PET, and immunohistochemical studies.
2006 · Lawrence M Cher, Carmel Murone, et al. · PubMed · 177
Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR.
2001 · R B Luwor, T G Johns, et al. · PubMed · 172
Lack of correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in non-small cell lung cancer assessed by 18F-Fluoromisonidazole and 18F-FDG PET.
2006 · Martin H Cherk, Serene S Foo, et al. · PubMed · 138
A Phase I Trial of Humanized Monoclonal Antibody A33 in Patients with Colorectal Carcinoma: Biodistribution, Pharmacokinetics, and Quantitative Tumor Uptake
2005 · Andrew M. Scott, Fook-Thean Lee, et al. · Clinical Cancer Research · 126
PDF
Assessing regional hypoxia in human renal tumours using 18 F‐fluoromisonidazole positron emission tomography
2005 · Nathan Lawrentschuk, Aurora M.T. Poon, et al. · British Journal of Urology · 121
The Immune Microenvironment, Genome-wide Copy Number Aberrations, and Survival in Mesothelioma
2017 · Bibhusal Thapa, Adriana Salcedo, et al. · Journal of Thoracic Oncology · 103
PDF
Treatment of Human Tumor Xenografts with Monoclonal Antibody 806 in Combination with a Prototypical Epidermal Growth Factor Receptor–Specific Antibody Generates Enhanced Antitumor Activity
2005 · Rushika M. Perera, Yoshitaka Narita, et al. · Clinical Cancer Research · 100
PDF
Antitumor efficacy of cytotoxic drugs and the monoclonal antibody 806 is enhanced by the EGF receptor inhibitor AG1478
2003 · Terrance G. Johns, Rodney B. Luwor, et al. · Proceedings of the National Academy of Sciences · 99
Angiotensin II receptor subtypes in the human central nervous system
1995 · Duncan P. MacGregor, Carmel Murone, et al. · Brain Research · 97
Specific Targeting, Biodistribution, and Lack of Immunogenicity of Chimeric Anti-GD3 Monoclonal Antibody KM871 in Patients With Metastatic Melanoma: Results of a Phase I Trial
2001 · Andrew M. Scott, Fook-Thean Lee, et al. · Journal of Clinical Oncology · 91
PD-L1 and Tumor Infiltrating Lymphocytes as Prognostic Markers in Resected NSCLC
2016 · Malaka Ameratunga, Khashayar Asadi, et al. · PLoS ONE · 86
PDF
Targeting EphA3 Inhibits Cancer Growth by Disrupting the Tumor Stromal Microenvironment
2014 · Mary E. Vail, Carmel Murone, et al. · Cancer Research · 84
Phase I Biodistribution and Pharmacokinetic Study of Lewis Y–Targeting Immunoconjugate CMD-193 in Patients with Advanced Epithelial Cancers
2009 · Rebecca A. Herbertson, Niall C. Tebbutt, et al. · Clinical Cancer Research · 74
PDF
A Phase I Biodistribution and Pharmacokinetic Trial of Humanized Monoclonal Antibody Hu3s193 in Patients with Advanced Epithelial Cancers that Express the Lewis-Y Antigen
2007 · Andrew M. Scott, Niall Tebbutt, et al. · Clinical Cancer Research · 74
PDF
Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer
2015 · A J Weickhardt, D S Williams, et al. · British Journal of Cancer · 68
PDF
Sox9 drives columnar differentiation of esophageal squamous epithelium: a possible role in the pathogenesis of Barrett's esophagus
2012 · Nicholas J. Clemons, David H. Wang, et al. · American Journal of Physiology-Gastrointestinal and Liver Physiology · 60
Distribution of bradykinin B2 receptors in sheep brain and spinal cord visualized by in vitro autoradiography
1997 · C. Murone, G. Paxinos, et al. · The Journal of Comparative Neurology · 55
Vascular endothelial growth factors (VEGF) and VEGF receptor expression as predictive biomarkers for benefit with bevacizumab in metastatic colorectal cancer (mCRC): Analysis of the phase III MAX study.
2011 · A. J. Weickhardt, D. Williams, et al. · Journal of Clinical Oncology · 53
A critical re-assessment of DNA repair gene promoter methylation in non-small cell lung carcinoma
2014 · Hongdo Do, Nicholas C. Wong, et al. · Scientific Reports · 51
PDF
Perindopril chronically inhibits angiotensin-converting enzyme in both the endothelium and adventitia of the internal mammary artery in patients with ischemic heart disease.
1997 · J L Zhuo, P Froomes, et al. · PubMed · 49
Phase II study of everolimus (RAD001) monotherapy as first-line treatment in advanced biliary tract cancer with biomarker exploration: the RADiChol Study
2018 · David K. Lau, Rebecca Y. Tay, et al. · British Journal of Cancer · 46
PDF
Villin Expression Is Frequently Lost in Poorly Differentiated Colon Cancer
2012 · Diego Arango, Sheren Al-Obaidi, et al. · American Journal Of Pathology · 41
PDF
Prognostic impact and the relevance of PTEN copy number alterations in patients with advanced colorectal cancer ( CRC ) receiving bevacizumab
2013 · Timothy J. Price, Jennifer E. Hardingham, et al. · Cancer Medicine · 35
PDF
Works count: 94
Citation count: 2,829
H-index: 27
I10-index: 41
Year
Topic
Type